Superantigens: A brief review with special emphasis on dermatologic diseases

Dermatology Online Journal

Volumn 14, Issue 2, 2008, Pages

  Solanki, Lakhan Singh ^a   Srivastava, Neeraj ^a   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANISODAMINE; DOXYCYCLINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN Y; KETAMINE; PIRFENIDONE; STAPHYLOCOCCUS PROTEIN A; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TOXIC SHOCK SYNDROME TOXIN 1; TRIPTOLIDE; HLA D ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN STRUCTURE; ATOPIC DERMATITIS; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INHIBITION; GENOME; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE MAMMARY TUMOR ONCOVIRUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; TOXIC SHOCK SYNDROME; ADULT; ANIMAL; ANTIGEN PRESENTATION; CHEMISTRY; CHILD; CLASSIFICATION; CUTANEOUS T CELL LYMPHOMA; FEMALE; IMMUNOLOGY; MALE; MICROBIOLOGY; PASSIVE IMMUNIZATION; SKIN DISEASE; STAPHYLOCOCCUS INFECTION;

ADULT; ANIMALS; ANTIGEN PRESENTATION; CHILD; DERMATITIS, ATOPIC; FEMALE; HLA-D ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL; SKIN DISEASES; STAPHYLOCOCCAL INFECTIONS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 41149090627     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol 2000; 8: 369-75.
2. Acharya KR, Passalacqua EF, Jones EY, Harlos K, Staurt DI, Brehm RD. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994; 367: 94-7.
3. Haynes BF, Fauci AS. Introduction to immune system. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw Hill; 2005. pp. 1907-30.
4. Bonventre PF, Weckbach L, Staneck J, Schlievert PM, Thompson M. Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun 1983; 40: 1023-29.
5. Weckbach LS,Thompson MR, Staneck JL, Bonventre PF. Rapid screening assay for toxic shock syndrome toxin production by Staphylococcus aureus. J Clin Microbiol 1984; 20: 18-22.
6. Rodgers R, Rich RR. Antigen and antigen presentation. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, editors. Textbook of clinical immunology: principles and practice. New York: Mosby; 2001. pp 7.1-7.17.
7. Huber BT, Hsu PN, Sutkowski N. Viral-encoded superantigens. Microbiol Rev 1996; 60: 473-82.
8. Rajagopalan G, Singh M, Sen MM, Murali NS, Nath KA, David CS. Endogenous superantigen shape response to exogenous superantigens. Clin Diagn Lab Immunol 2005; 12: 1119-22.
9. Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM. Superantigens: the good, the bad, and the ugly. Exp Biol Med 2001; 226: 164-76.
10. Choi Y, Kappler J W, Marrack P. A superantigen encoded in the reading frame of the 3′ log terminal repeat of mouse mammary tumour virus. Nature 1991; 350: 203-7.
11. Tai AK, Lin M, Chang F, Chen G, Hsiao F, Sutkowski N, Huber BT. Murine Vbeta3+ and Vbeta7+T cell subset are specific targets for the HERV-K18 Env superantigen. J Immunol 2006; 177: 3178-84.
12. Leung KP, Torres BA. Prevotella intermedia stimulate the expansion of Vbeta- specific CD4 (+) Tcells. Infect Immun 2000; 68: 5420-24.
13. Acharya KR, Baker MD. Superantigen: structure-function relationships. Int J Med Microbiol 2004; 293: 529-37.
14. Thomas DY, Jarraud S, Lemercier B, Cozon G, Echasserieau K, Etienne J, Gougeon ML, Lina G, Vandenesch F. Staphylococcal enterotoxin-like toxins U2, V, two new staphylococcal superantigens arising from recombination within the enterotoxin gene toxin. Infect Immun 2006; 74: 4724-34.
15. Donadini R, Wahlberg M, Kohsaka T, Ito Y, Fields BA. Crystallization and preliminary X-ray analysis of Yersinia pseudotuberculosis-derived mitogen. Acta Crystallogr D Biol Crystallogr 2003; 59: 1330-32.
16. Zhao Y, Li Z, Drozd SJ, Guo Y, Mourad W, Li H. Crystal structure of Mycoplasma arthiritidis mitogen complexed with HLA-DR1 reveals a novel superantigen fold and a dimerized superantigen-MHC complex. Structure 2004; 12: 277-88.
17. Vasil'eva GI, Kozolovskii VN, Mishan'kin BN, Mishan'kin MB. Cholera toxin as Vibrio cholera superantigen. Zh Mikrobiol Epidemiol Immunobiol 2002; 2: 50-55.
18. Ware RE. Immune abnormalities secondary to infectious diseases. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, editors. Textbook of clinical immunology: principles and practice. New York: Mosby; 2001. pp. 43.1-43.7.
19. Domiati-Saad R, Lipsky PE. Staphylococcal enterotoxin-A induces survival of VH3-expressing human B cells by binding to the VH region with low affinity. J Immunol 1998; 161: 1257-66.
20. Silverman GJ. B cell superantigens: possible role in immunodeficiency and autoimmunity. Semin Immunol 1998; 10: 43-55.
21. Patella V, Giuliano A, Bouvet JP, Marone G. Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. J Immunol 1998; 161: 5647-55.
22. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, et al. Crystallography and NMR system: a new software suite for macromolecular structure dertermination. Acta Crystallogr D 1998; 54: 905-21.
23. RCSB Protein data bank. http://www.pdb.org/pdb/results/results.do (accessed on Mar 6, 2007).
24. Singh S, Aiba S, Manome H, Tagami H. The effects of dexamethasone, cyclosporine, and vitamin D3 on the activation of dendritic cells stimulated by haptens. Arch Dermatol Res 1999; 291: 548-54.
25. Manome H, Aiba S, Singh S, Yoshino Y, Tagami H. Dexamethasone and cyclosporin A affect the maturation of monocyte-derived dendritic cells differently. Int Arch Allergy Immunol 2000; 122: 76-84.
26. Nairn R. Immunology. In: Brooks GF, Butel JS, Morse SA, editors. Javetz, Melnick and Adelberg's medical microbiology. New York: McGraw Hill; 2004. pp. 119-45
27. Sriskandan S, Faulkner L, Hopkins P. Streptococcal pyogenes: insight into the function of the streptococcal superantigens. Int J Biochem Cell Biol 2007; 39: 12-19.
28. Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Ann Rev Cell Biol 1993; 9: 101-28.
29. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. The Vbeta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989; 56: 27-35.
30. Fleischer B, Schrezenmeier H. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class-II molecules on accessory or target cells. J Exp Med 1988; 167: 1697-707.
31. Chatila T, Geha RS. Signal transduction by microbial superantigens via MHC class-II molecules. Immunol Rev 1993; 131: 43-59.
32. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ. Lack of complex correlation between emetic and T-cell stimulatory activities of staphylococcal enterotoxins. Infect Immun 1993; 61: 3175-83.
33. Lee PK, Zipoli MT, Weinberg AN, Swartz MN, Johnson RA. Pyodermas: Staphylococcus aureus, Streptococcus, and other gram-positive bacteria. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors.
34. Fitzpatrick's dermatology in general medicine. New York: McGraw Hill; 2003. pp. 1856-78.
35. Andrews MM, Parent EM, Barry M, Parsonnet J. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis and treatment. Clin Infect Dis 2001; 32: 1470-79.
36. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illness. Crit Rev Microbiol 1990; 17: 251-52.
37. Murono K, Fujita K, Yoshioka H. Microbiologic characterstics of exfoliative toxin producing Staphylococcus aureus. Pediatr Infect Dis 1988; 7: 313-15.
38. Ladhani S, Joannou CL, Lochrie DP, Evans RW, Poston SM. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev 1999; 12: 224-42.
39. Takagi Y, Futamura S, Asada Y. Action site of exfoliative toxin on keratinocytes. J Invest Dermatol 1990; 94: 582.
40. Gemmell CG. Staphylococcal scalded skin syndrome. J Med Microbiol 1995; 43: 318-27.
41. Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. Oxford: Blackwell Science; 2004. pp. 35.1-35.69.
42. Leung DY, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J, Kazemi LV, Kim MH, Trumble AE, Kotb M, et al. Evidence for a streptococcal superantigen-deriven process in acute guttate psoriasis. J Clin Invest 1995; 96: 1995-2106-12.
43. Zhao G, Feng X, Na A, Yongqiang J, Cai Q, Kong J, Ma H. Acute guttate psoriasis patients have positive Streptococcus hemolyticus throat cultures and elevated anti-streptococcal M6 protein titers. J Dermatol 2005; 32: 91-6.
44. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128: 39-42.
45. Henderson CA, Highet AS. Acute guttate psoriasis associated with Lancefield group C and group G cutaneous streptococcal infection. Br J Dermatol 1998; 118: 559-61.
46. Rosenberg EW, Noah PW, Zanolli MD, Skinner RB Jr, Bond MJ, Crutcher N. Use of rifampicin with penicillin and erythromycin in the treatment of psoriasis. J Am Acad Dermatol 1986; 14: 761-64.
47. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149: 530-4.
48. Leung DY, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunnol 1995; 155: 5018-21.
49. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995; 72: 308-11.
50. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994; 153: 1881-8.
51. Leung DY, Sullivan KE, Brown-Whitehorn TF, Fehringer AP, Allen S, Finkel TH, Washington RL, Makida R, Schlievert PM. Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr Res 1997; 42: 268-72.
52. Yamashiro Y, Nagata S, Oguchi S, Shimizu T. Selective increase of V beta 2+ T cells in the small intestine mucosa in Kawasaki disease. Pediatr Res 1996; 39: 264-66.
53. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385-88.
54. Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, Myones BL, Wheeler JG, Ruthazer R, Schlievert PM. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002; 140: 742-46.
55. Yoshioka T, Matsutani T, Toyosaki-Maeda T, Suzuki H, Uemura S, Suzuki R, Koike M, Hinuma Y. Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. Pediatr Res 2003; 53: 403-10.
56. Han MH, Jang KA, Sung KJ, Moon KC, Koh JK, Choi JH. A case of guttate psoriasis following Kawasaki disease. Br J Dermatol 2000; 142: 548-50.
57. Zvulunov A, Greenberg D, Cagnano E, Einhom M. Development of psoriatic lesions during acute and convalescent phases of Kawasaki disease. J Paediatr Child Health 2003; 39: 229-31.
58. Garty B, Mosseri R, Finkelstein Y. Guttate psoriasis following Kawasaki disease. Pediatr Dermatol 2001; 18: 507-8.
59. Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O. Staphylococcal enterotoxin B applied on intact and atopic skin induces dermatitis. Arch Dermatol 1996; 132: 27-33.
60. Skov L, Olsen JV, Giorno R, Schlievert PM, Baadsgaard O, Leung DY. Application of staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T-cells by superantigen-mediated mechanism. J Allergy Clin Immunol 2000; 105: 820-6.
61. Savinko T, Lauerma A, Lethtimaki S, Gombert M, Mauri ML, Fyhrquist-Vanni N, Dieu-Nosjean MC, Kemeny L, Wolff H, Homey B, Alenius H. Topical superantigen exposure induces epidermal accumulation of CD8+T cells, a mixed Th1/Th2-type dermatitis and vigorous production of IgE antibodies in the murine model of atopic dermatitis. J Immunol 2005; 175: 8320-6.
62. Taskapan MO, Kumar P. Role of staphylococcal superantigens in atopic dermatitis: from colonization to inflammation. Ann Allergy Immunol 2000; 84: 3-10.
63. Leung DYM. Atopic dermatitis: new insight and opportunities for therapeutic inetervention. J Allergy Clin Immunol 2000; 105: 860-76.
64. Leung DYM, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, Hanifin JM, Sampson HA. Presence of IgE antibodies to staphylococcal exotoxin on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 92: 1374-80.
65. Breuer K, Wittmann M, Bosche B, Kapp A, Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551-5.
66. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001; 108: 269-74.
67. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staph. aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001; 116: 658-63.
68. Leyden JJ, Kligman AM. The case for steroid-antibiotic combination. Br J Dermatol 1997; 96: 179-87.
69. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, Wahn U, Renz H. Evidence for a diseasae-promoting effect of staphylococcal aureus-derived exotoxin I in atopic dermatitis. J Allergy Immunol 2000; 105: 814-9.
70. Strickland I, Hauk PJ, Trumble AE, Picker LJ, Leung DY. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. J Invest Dermatol 1999; 112: 249-53.
71. Betlloch I, Ramon R, Silvestre JF, Carnero L, Albares MP, Banuls J. Acute juvenile pityriasis rubra pilaris: a superantigen mediated disease? Pediatr Dermatol 2001; 18: 411-14.
72. Mohrenschlager M, Abeck D. Further clinical evidence for involvement of bacterial superantigens in juvenile pityriasis rubra pilaris (PRP): report of two cases. Pediatr Dermatol 2002; 19: 569.
73. Jachow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor VB gene expression. Blood 1997; 87: 32-40.
74. Linnemann T, Gellrich S, Lukowsky A, Mielke A, Audring H, Sterry W. Polyclonal expansion of T-cells with the TCR V beta type of the tumour cell in lesions of cutaneous T-cell lymphoma: evidence for possible superantigen involvement. Br J Dermatol 2004; 150: 1013-7.
75. Tokura Y, Heald PW, Yan SL, Edelson RL. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol 1992; 98: 33-7.
76. Vonderheid EC, Boselli CM, Conroy M, Casaus I, Espinoza LC, Venkataramani P, Bigler RD, Hou JS. Evidence for restrictive V beta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 2005; 124: 651-61.
77. Tokura Y, Yagi H, Ohshima A, Kurokawa S, Wakita H, Yokote R, Shirahama S, Furukawa F, Takigawa M. Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol 1995; 133: 6-12.
78. 2-distributions in polyp-derived CD4+ and CD8+ T cells. Am J Rhinol 2006; 20: 534-9.
79. Liu T, Wang BQ, Zheng PY, He SH, Yang PC. Rhinosinusitis derived staphylococcal enterotoxin B plays a possible role in pathogenesis of food allergy. BMC Gastoenterology 2006; 6: 24.
80. Hashimoto T, Takishita M, Kosaka M, Sano T, Matsumoto T. Superantigens and autoantigens may be involved in the pathogenesis of gastric mucosa-associated lymphoid tissue lymphoma. Int J Hematol 2001; 74: 197-204.
81. Garson J, Creange A, Dolei A, Ferrante P, Jouvin-Marche E, Marche PN, Reiger F, Ruprecht K, Saresella M, Sotgiu S, Tedder R, Perron H. MSRV, synectin and the role of endogenous retroviral proteins in demyelination. Mult Scler 2005; 11: 246-50.
82. Ochi H, Osoegava M, Murai H, Minohara M, Taniwaki T, Kira J. Presence of IgE antibodies to bacterial superantigens and increased IL-13 producing-T cells in myelitic patients with atopic diathesis. Int Arch Allergy Immunol 2004; 134: 41-48.
83. Schiffenbauer J, Johnson HM, Butfiloski E, Wegrzyn L, Soos JM. Staphylococcal enterotoxins reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 1993; 90: 8543-6.
84. Kraft M, Filsinger S, Kramer KL, Kabelitz D, Hansch GM, Schoels M. Synovial fibroblasts as target cells for staphylococcal enterotoxin-induced T cell cytotoxicity. Immunol 1998; 93: 20-5.
85. Shio MT, Ribeiro-Dias F, Timenetsky J, Jancar S. PAF is involved in the Mycoplasma arthritidis superantigen-triggering pathway for iNOS and Cox-2 expression in murine peritoneal cells. Exp Cell Res 2004; 298: 296-304.
86. Sicat J, Sutkowski N, Huber BT. Expression of human endogenous retrovirus HERV-K18 superantigen is elevated in juvenile rheumatoid arthritis. J Rheumatol 2006; 22: 1821-31.
87. Evereklioglu C. Current concepts in the etiology and treatment of Bechet disease. Surv Ophthalmol 2005; 50: 297-350.
88. Hirohata S, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Bechets's disease (BD). Clin Exp Immunol 1998; 112: 17-24.
89. Popa ER, Stegeman CA, Kallenberg CGM, Tervaert JWC. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002; 4: 77-9.
90. Stegeman CA, Cohen Tervaert JW, Slutier WJ, Manson WL, deJong PE, Kallenberg CGM. Association of chronic nasal carriage of S. aureus and higher relapse rate in Wegener's granulomatosis. Ann Int Med 1994; 120: 12-7.
91. Hamidou M, Belizna C. Superantigens and vasculitis. Ann Med Interne (Paris) 2003; 154: 96-100.
92. Kraine MR, Tisch RM. The role of environmental factors in insulin-dependent diabetes mellitus: A unsolved issue. Environ Health Perspect 1999; 107: 777-81.
93. Azar GA, Thibodeau J. Human endogenous retrovirus IDDMK(1, 2)22 and mouse mammary tumor virus superantigens differ in their ability to stimulate murine T cell hybridomas. Immunol Lett 2002; 81: 87-91.
94. Pied S, Voegtle D, Marussig M, Renia L, Miltgen F, Mazier D, Cazenave PA. Evidence for superantigenic activity during murine malaria infection. Int Immunol 1997; 9: 17-25.
95. Goodier M, Fey P, Eichmann K, Langhorne J. Human peripheral blood gamma delta T cells respond to antigens of Plasmodium falciparum. Int Immunol 1992; 4: 33-41.
96. Ohmen JD, Barnes PF, Grisso CL, Bloom BR, Modlin RL. Evidence for a superantigen in human tuberculosis. Immunity 1994; 1: 35-43.
97. Ohmen JD, Modlin RL. Evidence for a superantigen in the pathogenesis of tuberculosis. Springer Semin Immunopathol 1996; 17: 375-84.
98. Sutkowski N, Palkama T, Ciurli C, Sekaly RP. An Epstein-Barr virus-associated superantigen. J Exp Med 1996; 184: 971-80.
99. Hsiao FC, Lin M, Tai A, Chen G, Huber BT. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J Immunol 2006; 177: 2056-60.
100. Torres BA, Tanabe T, Yamamoto JK, Johnson HM. HIV encodes for its own CD4 T cell superantigen mitogen. Biochem Biophy Res Commun 1996; 225: 672-78.
101. Schmidt S, Balzer S, Nullen C, Schmidt M, Pohl C, VonRucker A, Klockgether T. Immunomodulatory effects of glatiramer acetate on superantigen-and mitogen-induced T-cell stimulation in vitro. Mult Scler 2002; 8: 307-9.
102. Perumal J, Filippi M, Ford C, Johnson K, Lisak R, Metz L, Tselis A, Tullman M, Khan O. Glatiramer acetate therapy for multiple sclerosis: a review. Expert Opin Drug Metab Toxicol 2006; 2: 1019-29.
103. Derenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Anderson J, Norrby-Teglund A. Intravenous immuloglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-40.
104. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006; 58: 117-24.
105. Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006; 43: 743-46.
106. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003; 47; 3630-33.
107. Nakagawa S, Kushiya K, Taneike I, Imanishi K, Uchiyama T, Yamamoto T. Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin-1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice. Clin Diagn Lab Immunol 2005; 12: 399-408.
108. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 2002; 70: 2989-94.
109. Kawasaki C, Kawasaki T, Ogata M, Nandate K, Shigematsu A. Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anaesth 2001; 48: 819-23.
110. Krakauer T, Chen X, Howard OM, Young HA. Triptolide attenuates endotoxin and staphylococcal exotoxin-induced T cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol 2005; 27: 53-66.
111. LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 2002; 70: 2278-81.